Targeted mRNA demethylation using an engineered dCas13b-ALKBH5 fusion protein.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
04 06 2020
Historique:
accepted: 08 04 2020
revised: 01 04 2020
received: 22 11 2019
pubmed: 2 5 2020
medline: 18 8 2020
entrez: 2 5 2020
Statut: ppublish

Résumé

Studies on biological functions of N6-methyladenosine (m6A) modification in mRNA have drawn significant attention in recent years. Here we describe the construction and characterization of a CRISPR-Cas13b-based tool for targeted demethylation of specific mRNA. A fusion protein, named dm6ACRISPR, was created by linking a catalytically inactive Type VI-B Cas13 enzyme from Prevotella sp. P5-125 (dPspCas13b) to m6A demethylase AlkB homolog 5 (ALKBH5). dm6ACRISPR specifically demethylates m6A of targeted mRNA such as cytochrome b5 form A (CYB5A) to increase its mRNA stability. It can also demethylate β-catenin-encoding CTNNB1 mRNA that contains multiple m6A sites to trigger its translation. In addition, the dm6ACRISPR system incurs efficient demethylation of targeted epitranscriptome transcripts with limited off-target effects. Targeted demethylation of transcripts coding for oncoproteins such as epidermal growth factor receptor (EGFR) and MYC can suppress proliferation of cancer cells. Together, we provide a programmable and in vivo manipulation tool to study mRNA modification of specific genes and their related biological functions.

Identifiants

pubmed: 32356894
pii: 5827664
doi: 10.1093/nar/gkaa269
pmc: PMC7261189
doi:

Substances chimiques

5' Untranslated Regions 0
CRISPR-Associated Proteins 0
RNA, Messenger 0
Recombinant Fusion Proteins 0
N-methyladenosine CLE6G00625
AlkB Homolog 5, RNA Demethylase EC 1.14.11.-
Adenosine K72T3FS567

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

5684-5694

Subventions

Organisme : NCI NIH HHS
ID : R01 CA251698
Pays : United States

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

Nat Rev Mol Cell Biol. 2019 Aug;20(8):490-507
pubmed: 31147612
J Am Chem Soc. 2018 Sep 26;140(38):11974-11981
pubmed: 30183280
J Clin Invest. 2015 May;125(5):1998-2006
pubmed: 25866970
Nat Commun. 2019 May 6;10(1):2065
pubmed: 31061416
Nat Methods. 2018 Jul;15(7):535-538
pubmed: 29967493
Nature. 2012 Apr 29;485(7397):201-6
pubmed: 22575960
Cell. 2012 Jun 22;149(7):1635-46
pubmed: 22608085
Cell. 2018 Jan 11;172(1-2):90-105.e23
pubmed: 29249359
Oncogene. 2017 Apr 27;36(17):2337-2344
pubmed: 27775071
Cell. 2018 Apr 19;173(3):665-676.e14
pubmed: 29551272
Cell. 2017 Jun 15;169(7):1187-1200
pubmed: 28622506
Nature. 2014 Jan 2;505(7481):117-20
pubmed: 24284625
Nature. 2017 Aug 17;548(7667):338-342
pubmed: 28792938
J Biol Chem. 2014 Apr 25;289(17):11571-83
pubmed: 24616105
Nat Commun. 2018 Feb 9;9(1):597
pubmed: 29426832
Nature. 2017 Feb 23;542(7642):475-478
pubmed: 28192787
Angew Chem Int Ed Engl. 2019 Apr 1;58(15):5028-5032
pubmed: 30756480
Nat Biotechnol. 2015 May;33(5):510-7
pubmed: 25849900
Science. 2016 Aug 5;353(6299):aaf5573
pubmed: 27256883
Nat Rev Mol Cell Biol. 2016 Jan;17(1):5-15
pubmed: 26670017
Cell. 2015 Jun 4;161(6):1388-99
pubmed: 26046440
Cell. 2013 Dec 19;155(7):1479-91
pubmed: 24360272
Cell. 2016 Sep 22;167(1):233-247.e17
pubmed: 27662091
Nucleic Acids Res. 2007;35(1):100-12
pubmed: 17151075
Nat Rev Mol Cell Biol. 2019 Oct;20(10):608-624
pubmed: 31520073
Nat Biotechnol. 2016 Oct;34(10):1060-1065
pubmed: 27571369
Nature. 2018 Mar 8;555(7695):256-259
pubmed: 29489750
Nat Methods. 2015 May;12(5):401-403
pubmed: 25775043
Cell Death Differ. 2020 Jan;27(1):255-268
pubmed: 31114028
Nature. 2015 Oct 22;526(7574):591-4
pubmed: 26458103
Cell Res. 2013 May;23(5):720-3
pubmed: 23545779
Angew Chem Int Ed Engl. 2018 Dec 3;57(49):15995-16000
pubmed: 30345651
Nat Commun. 2017 Jul 11;8:16026
pubmed: 28695892
Nature. 2017 Sep 14;549(7671):273-276
pubmed: 28869969
Nature. 2017 Oct 12;550(7675):280-284
pubmed: 28976959
Nucleic Acids Res. 2017 Feb 28;45(4):1703-1713
pubmed: 27899645
Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):E325-E333
pubmed: 29279410
Science. 2017 Nov 24;358(6366):1019-1027
pubmed: 29070703
Cell Discov. 2018 Feb 27;4:10
pubmed: 29507755
Mol Cell. 2013 Jan 10;49(1):18-29
pubmed: 23177736
Nature. 2017 Mar 23;543(7646):573-576
pubmed: 28297716
Cell Discov. 2016 May 03;2:16009
pubmed: 27462456
Nat Biotechnol. 2017 Apr;35(4):371-376
pubmed: 28191901

Auteurs

Jiexin Li (J)

Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China.

Zhuojia Chen (Z)

Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.

Feng Chen (F)

Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China.

Guoyou Xie (G)

Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China.

Yuyi Ling (Y)

Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China.

Yanxi Peng (Y)

Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China.

Yu Lin (Y)

Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China.
Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital,Southern Medical University, Guangzhou, Guangdong 510006, China.

Nan Luo (N)

Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China.

Cheng-Ming Chiang (CM)

Simmons Comprehensive Cancer Center, Department of Pharmacology, and Department of Biochemistry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.

Hongsheng Wang (H)

Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH